Skip to main content

Table 2 Antibody titres over 96 weeks of AADvac1 treatment

From: FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease

 

GMT

Week + 4

Week + 8

Week + 12

Week + 16

Week + 20

Week + 24

Week + 36

Week + 44

Week + 48

Week + 60

Week + 72

Week + 76

Week + 84

Week + 96

Anti-KLH

260.0

8128

36,784

68,023

102,453

127,972

68,870

42,043

30,967

141,323

76,711

172,828

177,672

116,545

(lower CI)

103.4

2763

21,622

45,268

62,490

77,347

47,757

28,870

21,922

101,408

52,550

132,513

158,315

83,702

(upper CI)

653.7

23,906

62,578

102,216

167,973

211,734

99,316

61,225

43,742

196,949

111,982

225,409

199,395

162,275

Anti-peptide IgG

219.1

7318

18,382

26,868

29,047

36,697

16,483

8908

6789

23,541

9541

32,023

17,741

6679

(lower CI)

104.5

3300

10,084

16,320

18,244

22,759

10,642

5233

3913

14,811

5819

20,397

10,941

3580

(upper CI)

459.2

16,228

33,509

44,233

46,246

59,171

25,529

15,163

11,781

37,417

15,646

50,273

28,767

12,462

Anti-peptide IgM

1659

16,586

40,048

66,087

69,789

72,154

29,150

21,702

18,272

37,301

20,904

45,288

29,153

21,018

(lower CI)

596.7

8075

25,606

47,284

49,429

53,114

19,298

13,862

11,250

22,220

11,621

23,581

15,903

10,887

(upper CI)

4612

34,068

62,634

92,366

98,536

98,019

44,032

33,976

29,676

62,616

37,602

86,980

53,443

40,575

  1. Ig Immunoglobulin, KLH Keyhole limpet haemocyanin
  2. Basic vaccination regimen is shown in bold